Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y

PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.

Zacks Investment Research • May 7, 2026

Diamond Hill Small-Mid Cap Strategy Q1 2026 Portfolio Activity

We do not believe Humana's current share price reflects the company's earnings power, and as industry conditions normalize, we believe it can return to target margins over the long term. We initiated a position in Antero Resources, a natural gas exploration and production company, to gain exposure given our constructive long-term outlook for US natural gas. We exited our position in First Advantage, a leader in the background check space, to pursue other opportunities with less macro exposure and AI-disruption concerns.

Seeking Alpha • May 7, 2026

Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript

Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations

Mitigating category headwinds with market share gains through implementation of Three‑S plan. Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed ® , Opill ® , and ellaOne ® brands.

PRNewsWire • May 6, 2026

Perrigo (PRGO) Q1 Earnings Beat Estimates

Perrigo (PRGO) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.6 per share a year ago.

Zacks Investment Research • May 6, 2026

Perrigo Completes Divestiture of Dermacosmetics Business

Advances key Three-S plan pillar, streamlining portfolio Upfront net proceeds of approximately €306 million will enable debt reduction DUBLIN, April 30, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading global provider of consumer health products, today announced that it has completed the previously announced sale of its branded Dermacosmetics business to Karo Healthcare ("Karo") for total consideration of up to €332.6 million. The transaction consists of €305.6 million in upfront cash, including €5.6 million in net working capital adjustments, and up to an additional €27.0 million contingent on the achievement of net sales milestones over the next three years.

PRNewsWire • Apr 30, 2026

Perrigo Announces Quarterly Dividend

DUBLIN, April 29, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that its Board of Directors has approved a quarterly dividend of $0.29 per share, or $1.16 per share on an annualized basis. The cash dividend is payable on June 16, 2026, to shareholders of record on May 29, 2026.

PRNewsWire • Apr 29, 2026

Analysts Estimate Perrigo (PRGO) to Report a Decline in Earnings: What to Look Out for

Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 29, 2026

3 Healthcare Stocks Paying the Highest Dividends in the Sector Right Now

Perrigo sports a forward dividend yield nearing 10%, but this high yield is highly reflective of high uncertainty over the company's future performance. Despite a mixed dividend growth track record, an ongoing catalyst may make Healthpeak Properties appealing to investors focused on capital growth.

The Motley Fool • Apr 29, 2026

O'Keefe Stevens Advisory Q1 2026 Winners And Laggards

The first quarter of 2026 was the first negative quarter for the S&P 500 since Q1 2025's tariff shock. On January 27, Corning and Meta announced a multi-year agreement worth up to $6 billion for optical fiber, cable, and connectivity for U.S. AI data centers, anchored at the Hickory, North Carolina, plant that Corning says will become the world's largest fiber-optic cable facility. Sphere's operating results continue to surprise us to the upside.

Seeking Alpha • Apr 28, 2026